Press releases

New Advancements Enable Quantitative Analysis of Lipids in Cells

Las Vegas - November 15, 2004 - QuantomiX latest product, a proprietary solution for lipid imaging and quantification, will be demonstrated at NAASO 2004 in Las Vegas. The breakthrough technology is especially relevant for NAASO, the North American Organization for the Study of Obesity, for whom the study of obesity, diabetes, and other lipid disorders is paramount. Applications of QuantomiX WETSEM^TM technology in obesity and diabetes will be shown in workshop and paper presentations to be held for NAASO meeting attendees.

Applying recent advances in nanotechnology, QuantomiX developed the WETSEM^TM technology, which enables direct imaging of lipids in cells and tissues with scanning electron microscopes. The technology uses a very thin membrane that is transparent to an electron beam but impervious to water, and sufficiently strong to resist a one-atmosphere pressure difference.

Lipid accumulation plays a key role in metabolic syndrome. Using QuantomiX technology, researchers and clinicians can now gain insight into diabetes and obesity by imaging and quantifying lipid accumulation in cells and tissues. Leaders in the field expect the technology to improve drug discovery and enable early diagnosis of diabetes and other lipid disorders.

"We believe that this discovery will shed light on how our body stores fat and will provide a practical and accurate tool for drug discovery and diagnostics," asserts Ory Zik, QuantomiX CEO. Barbara Corkey, Ph.D., Professor of Medicine and Biochemistry and Director of the Obesity Research Center at Boston Medical Center, Boston University, and head of the North American Organization for the Study of Obesity (NAASO), is equally enthusiastic. "QuantomiX technology enables us to quantitatively study lipid accumulation, in a way that we could not do before," she declares.

QuantomiX is currently collaborating with scientists at major research institutions in the United States and Europe to further develop its technology and pioneer its use in future medical diagnostic and industrial applications.

About QuantomiX

QuantomiX develops and commercializes breakthrough solutions based on its proprietary WETSEM^TM technology. This technology enables scanning electron microscopes (SEM) to image and analyze wet samples such as cells, tissue biopsies, foods and ink, in their native environment. Eliminating the need for time-consuming preparation procedures, the WETSEM^TM technology ensures that sample integrity is not compromised by artifacts. QuantomiX innovative technology opens new opportunities for application-specific tools to improve drug discovery, and advances treatment and diagnostic solutions for the medical and pharmaceutical markets.

Established in 2001, QuantomiX operates in Israel, the US, Europe and Japan. The company's managerial team and development staff include an experienced cadre of business and industry professionals.